ABOUT US / TECHNOLOGY / NEWS / CONTACT

SWElife grant of SEK 2.8 million

November 15, 2018

Apoglyx is extremely pleased to announce that, for the second time, we have received a grant from SWElife, the Swedish national innovation programme. We see this as validation that our approach to developing new diabetes treatment options is novel. The grant of up to SEK 2.8M will enable us to progress through pre-clinical activities in preparation for IND/CTA-enabling activities.

Om Swelife: för ett konkurrenskraftigt life science-system i Sverige

Swelife stödjer samverkan mellan akademi, näringsliv och hälso- och sjukvård med målet att stärka life science i Sverige och förbättra folkhälsan. Det är ett strategiskt innovationsprogram som finansieras av regeringen via innovationsmyndigheten Vinnova och av programmets deltagande parter.

www.swelife.se

US patent granted

July 03, 2018

On 3 July 2018, the United States Patent and Trademark office issued US Patent No.: 10,011,597 B2. This is a major milestone for Apoglyx as our first patent family has now been granted in a major market. The national phase examinations are continuing in other countries.

ABOUT US / TECHNOLOGY / NEWS / CONTACT